{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:56:59Z","timestamp":1782482219540,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1124\/molpharm.122.000643","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T21:05:46Z","timestamp":1692392746000},"page":"195-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a Selective and High Affinity Radioligand, [3H]VU6013720, for the M4 Muscarinic Receptor"],"prefix":"10.1016","volume":"104","author":[{"given":"Aidong","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley E.","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Billard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-5103","authenticated-orcid":false,"given":"Alice L.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Engers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Moehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerri M.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6009-8212","authenticated-orcid":false,"given":"Colleen M.","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.122.000643_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1101\/SQB.1988.053.01.033","article-title":"Functional role of muscarinic acetylcholine receptor subtype diversity","volume":"53","author":"Ashkenazi","year":"1988","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.1124\/molpharm.122.000643_bib2","doi-asserted-by":"crossref","first-page":"128479","DOI":"10.1016\/j.bmcl.2021.128479","article-title":"Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor","volume":"56","author":"Bender","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/molpharm.122.000643_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0014-5793(88)80648-3","article-title":"The striatum and cerebral cortex express different muscarinic receptor mRNAs","volume":"230","author":"Brann","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1124\/molpharm.122.000643_bib4","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1021\/cn500128b","article-title":"Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents","volume":"5","author":"Bubser","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/molpharm.122.000643_bib5","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1523\/JNEUROSCI.08-12-04646.1988","article-title":"Localization of a family of muscarinic receptor mRNAs in rat brain","volume":"8","author":"Buckley","year":"1988","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.122.000643_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14656560903426171","article-title":"Treatment strategies for dystonia","volume":"11","author":"Cloud","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/molpharm.122.000643_bib7","doi-asserted-by":"crossref","first-page":"112989","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatry Res"},{"key":"10.1124\/molpharm.122.000643_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cmdc.201800710","article-title":"11 C-Labeled VU0467485\/AZ13713945 and Its Analogues for Imaging Muscarinic Acetylcholine Receptor Subtype\u20054","volume":"14","author":"Deng","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1124\/molpharm.122.000643_bib9","doi-asserted-by":"crossref","first-page":"127326","DOI":"10.1016\/j.bmcl.2020.127326","article-title":"Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[(11)C]methoxyphenethyl)pyridazin-3(2H)-one, a (11)C-labeled d-amino acid oxidase (DAAO) inhibitor for PET imaging","volume":"30","author":"Deng","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/molpharm.122.000643_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0079-6123(08)60922-X","article-title":"Antimuscarinic drugs in the treatment of movement disorders","volume":"84","author":"Fahn","year":"1990","journal-title":"Prog Brain Res"},{"key":"10.1124\/molpharm.122.000643_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.neuropharm.2018.01.028","article-title":"Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases","volume":"136","author":"Felder","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.122.000643_bib12","doi-asserted-by":"crossref","first-page":"113201","DOI":"10.1016\/j.bbr.2021.113201","article-title":"Targeting muscarinic receptors to treat schizophrenia","volume":"405","author":"Foster","year":"2021","journal-title":"Behav Brain Res"},{"key":"10.1124\/molpharm.122.000643_bib13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"10.1124\/molpharm.122.000643_bib14","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.96.18.10483","article-title":"Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice","volume":"96","author":"Gomeza","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.122.000643_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.apsb.2022.07.008","article-title":"Structure-activity relationship of pyrazol-4-yl-pyridine derivatives and identification of a radiofluorinated probe for imaging the muscarinic acetylcholine receptor M4","volume":"13","author":"Haider","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/molpharm.122.000643_bib16","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.2174\/138161206778522056","article-title":"Muscarinic acetylcholine receptors","volume":"12","author":"Ishii","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1124\/molpharm.122.000643_bib17","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.3843-09.2010","article-title":"A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors","volume":"30","author":"Jeon","year":"2010","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.122.000643_bib18","first-page":"CD003735","article-title":"Anticholinergics for symptomatic management of Parkinson\u2019s disease","volume":"2002","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/molpharm.122.000643_bib19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.neuropharm.2017.11.018","article-title":"Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer\u2019s disease","volume":"136","author":"Lebois","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.122.000643_bib20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0024-3205(93)90300-R","article-title":"Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain","volume":"52","author":"Levey","year":"1993","journal-title":"Life Sci"},{"key":"10.1124\/molpharm.122.000643_bib21","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","article-title":"Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies","volume":"11","author":"Levey","year":"1991","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.122.000643_bib22","doi-asserted-by":"crossref","first-page":"eabg3684","DOI":"10.1126\/scitranslmed.abg3684","article-title":"The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer\u2019s disease","volume":"14","author":"Li","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1124\/molpharm.122.000643_bib23","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsptsci.0c00162","article-title":"Discovery of the First Selective M4 in Vivo Antiparkinsonian and Antidystonic Efficacy","volume":"4","author":"Moehle","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1124\/molpharm.122.000643_bib24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/mds.27740","article-title":"Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders","volume":"34","author":"Moehle","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/molpharm.122.000643_bib25","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.neuron.2017.12.008","article-title":"Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor","volume":"96","author":"Moehle","year":"2017","journal-title":"Neuron"},{"key":"10.1124\/molpharm.122.000643_bib26","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.tips.2019.10.007","article-title":"Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders","volume":"40","author":"Moran","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.122.000643_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/mol.117.110114","article-title":"Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators","volume":"93","author":"O\u2019Brien","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.122.000643_bib28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0026-895X(25)10203-4","article-title":"Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq\/11","volume":"45","author":"Offermanns","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.122.000643_bib29","doi-asserted-by":"crossref","first-page":"14078","DOI":"10.1073\/pnas.1512812112","article-title":"Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice","volume":"112","author":"Pancani","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.122.000643_bib30","first-page":"6","article-title":"Structural basis of muscarinic acetylcholine receptor subtype diversity","author":"Peralta","year":"1988","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.122.000643_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/mol.114.091785","article-title":"Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites","volume":"86","author":"Schober","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.122.000643_bib32","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1021\/acsmedchemlett.1c00363","article-title":"Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist","volume":"12","author":"Spock","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/molpharm.122.000643_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.apha.2019.05.001","article-title":"Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders","volume":"86","author":"Teal","year":"2019","journal-title":"Adv Pharmacol"},{"key":"10.1124\/molpharm.122.000643_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0165-3806(95)01515-9","article-title":"Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age","volume":"92","author":"Tice","year":"1996","journal-title":"Brain Res Dev Brain Res"},{"key":"10.1124\/molpharm.122.000643_bib35","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/acs.jmedchem.9b01406","article-title":"Discovery of [11C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases","volume":"63","author":"Tong","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.122.000643_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0079-6123(08)62385-7","article-title":"Advances and limitations of the molecular neuroanatomy of cholinergic receptors: the example of multiple muscarinic receptors","volume":"98","author":"Vilar\u00f3","year":"1993","journal-title":"Prog Brain Res"},{"key":"10.1124\/molpharm.122.000643_bib37","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1073\/pnas.87.18.7050","article-title":"Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia","volume":"87","author":"Weiner","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.122.000643_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.1995.tb17474.x","article-title":"Development of selective antisera for muscarinic cholinergic receptor subtypes","volume":"757","author":"Wolfe","year":"1995","journal-title":"Ann N Y Acad Sci"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.122.000643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:26:45Z","timestamp":1739957205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0026895X24000580"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.122.000643","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a Selective and High Affinity Radioligand, [3H]VU6013720, for the M4 Muscarinic Receptor","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.122.000643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}